February 15, 2007Cancer ResearchOpen Access

Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury

View Full Paper

Ask AI

Bookmark

Why the study?

Does HSP90 inhibition increase susceptibility to doxorubicin-induced cardiac injury in rat models?

Population

In vivo rat model and isolated cardiomyocytes

Design

Preclinical

Authors

KGKathleen L. GabrielsonJohns Hopkins University DBDjahida BedjaHoward Hughes Medical Institute SPScott PinJohns Hopkins University

Discussion

Member takes

Implication

May warrant caution with HSP90 inhibitors during doxorubicin therapy; hypothesis-generating for trastuzumab synergy, pending clinical studies.

Structured PICO

Does HSP90 inhibition increase susceptibility to doxorubicin-induced cardiac injury in rat models?

Population

In vivo rat model and isolated cardiomyocytes

Intervention

Doxorubicin treatment, with or without HSP90 inhibitor (17-(allylamino)-17-demethoxygeldanamycin)

Outcome

Cardiac damage, loss of cardiac function, and molecular changes (ErbB2, neuregulin 1beta, Akt signaling, HSP90 levels)surrogate

HSP90 acts as a protective chaperone for ErbB2 during doxorubicin treatment, providing a mechanistic explanation for the synergistic cardiotoxicity of doxorubicin and anti-ErbB2 therapies like trastuzumab.

Cite This Study

Gabrielson et al. (2007) studied this question.

synapsesocial.com/papers/6a73e3580375516f85f161d3 https://doi.org/10.1158/0008-5472.can-06-3721

Topics

Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Implication

May warrant caution with HSP90 inhibitors during doxorubicin therapy; hypothesis-generating for trastuzumab synergy, pending clinical studies.

Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider